Pediatric patients with non–central nervous system, TRK fusion–positive cancers who were enrolled to the phase 1/2 SCOUT and phase 2 NAVIGATE trials and received larotrectinib continued to experience rapid and durable tumor-agnostic efficacy and prolonged survival.
Pediatric patients with non–central nervous system (CNS), TRK fusion–positive cancers who were enrolled to the phase 1/2 SCOUT (NCT02637687) and phase 2 NAVIGATE (NCT02576431) trials and received larotrectinib (Vitrakvi) continued to experience rapid and durable tumor-agnostic efficacy and prolonged survival, according to insights from an expanded dataset featured in a poster presentation during the 2022 ASCO Annual Meeting.1
These findings demonstrate the need to identify NTRK gene fusions, which are oncogenic drivers in various tumor types across all ages but have a high incidence (> 90%) in pediatric solid tumors, according to Leo Mascarenhas, MD, MS, deputy director at the Cancer and Blood Disease Institute, and the University of Southern California Keck School of Medicine, and colleagues.
“In this expanded dataset of pediatric patients with a longer follow-up, larotrectinib continues to demonstrate a rapid and durable efficacy with an extended survival benefit. Larotrectinib had a favorable safety profile with no new safety signals,” Mascarenhas said during a presentation on the poster. “These results highlight the importance of identifying NTRK gene fusions in pediatric patients with solid tumors to identify those patients that will most likely benefit from treatment with TRK inhibitor therapy.”
The first-in-class, CNS-active, highly selective TRK inhibitor, larotrectinib, is currently approved for both pediatric and adult patients who have TRK fusion–positive cancer. Larotrectinib previously demonstrated an objective response rate (ORR) of 88% across 78 pediatric patients with non-CNS cancer, according to van Tilburg et al.2
In this analysis of an expanded dataset of pediatric patients with TRK fusion-positive cancer, patients aged 18 years and younger with non-CNS TRK fusion–positive cancer were evaluated in the SCOUT and NAVIGATE trials.
Between the 2 studies, 94 patients were enrolled by July 20, 2021, the data cutoff. The pediatric patients with non-primary CNS TRK fusion cancer had tumor types consisting of infantile fibrosarcoma (52%), other soft tissue sarcoma (40%), congenital mesoblastic nephroma (2%), thyroid cancer (2%), bone sarcoma (1%), breast cancer (1%), and melanoma (1%). NTRK gene fusion status was determined prior to enrollment with patients having NTRK1 (43%), NTRK2 (3%), or NTRK3 (54%) gene fusions.
The median age of those enrolled in the trial was 2.2 years (range 0–18 years), and out of the 62 (66%) participants who received prior systemic therapy, 48 (51%) received 2 or less lines with 14 (15%) receiving 3 or more. Additionally, 75 (80%) patients had a Lansky/Karnofsky performance status of 90-100 with the other 19 patients ranging between 50-60.
Most patients enrolled in the expanded dataset received initial larotrectinib at a dose of 100 mg/m2 twice daily (BID; (n = 85) with 3 patients administered either 9.6-55 mg/m2 of larotrectinib BID and 6 administered 17.3-120 mg/m2 BID.
The primary end point was the investigator assessed ORR per RECIST v1.1 with secondary endpoints including duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety.
For the 93 evaluable patients included, larotrectinib was shown to be efficacious across most tumor types with an INV-assessed best ORR of 84% (95% CI, 75%–91%). There were 35 patients (38%) who had a complete response (CR), which included 2 pending confirmation and 10 pathological CR, 43 (46%) who had a partial response with 2 pending confirmation, 11 (12%) with stable disease, 2 (2%) with progressive disease, and 2 (2%) who were not determined.
The median DOR was 43.3 months (95% CI, 23.4-NE) with a median follow-up of 26.0 months, and a median time to response of 1.8 months. Median PFS was 37.4 months (95% CI 22-NE) and OS was not reached at the median follow-up of 21.2 and 30.3 months, respectively. Additionally, the 36-month OS rate was 93% (95% CI, 86-99).
In terms of safety, no new or unexpected treatment-emergent adverse effects and no treatment-related deaths were reported. Treatment-related adverse events (TRAEs) occurred in 81% of patients with 23% being considered grade 1, 28% grade 2, 25% grade 3, and 5% grade 4. Increased aspartate aminotransferase was the most common TRAE which occurred in 31 patients (33%). Other common TRAEs included vomiting, increased alanine aminotransferase, anemia, decreased neutrophil count, nausea, and more.
Further, a total of 12% of patients had neurological TRAEs occur, with 5% considered grade 1, 4% grade 2, and 2% grade 3. The most common neurological TRAE was headache which occurred in 5 patients (5%). Other neurological TRAEs included insomnia, agitation, dizziness, irritability, gait disturbance, and restlessness. Four patients (4%) ended up discontinuing treatment due to TRAEs.